Hikma Pharmaceuticals PLC

LSE:HIK Stock Report

Market Cap: UK£4.1b

Hikma Pharmaceuticals Future Growth

Future criteria checks 2/6

Hikma Pharmaceuticals is forecast to grow earnings and revenue by 12.9% and 5.9% per annum respectively. EPS is expected to grow by 13.3% per annum. Return on equity is forecast to be 19.3% in 3 years.

Key information

12.9%

Earnings growth rate

13.29%

EPS growth rate

Pharmaceuticals earnings growth12.8%
Revenue growth rate5.9%
Future return on equity19.29%
Analyst coverage

Good

Last updated19 Aug 2025

Recent future growth updates

Recent updates

Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)

Aug 02
Earnings Tell The Story For Hikma Pharmaceuticals PLC (LON:HIK)

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Jun 19
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects

Apr 08
Investors Appear Satisfied With Hikma Pharmaceuticals PLC's (LON:HIK) Prospects

Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly

Mar 17
Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
User avatar

R&D Investments And Xellia Acquisition Will Expand Product Pipeline And Revenue Prospects

Strategic R&D investments and the acquisition of Xellia are expected to enhance Hikma's product pipeline, manufacturing capabilities, and revenue growth.

Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Nov 11
Hikma Pharmaceuticals PLC's (LON:HIK) P/E Is On The Mark

Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Oct 24
Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?

Earnings and Revenue Growth Forecasts

LSE:HIK - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20273,7105814738039
12/31/20263,49151043776010
12/31/20253,32144935667210
6/30/20253,216371228527N/A
3/31/20253,172365279546N/A
12/31/20243,127359329564N/A
9/30/20243,072322354574N/A
6/30/20243,017285379584N/A
3/31/20242,946238392596N/A
12/31/20232,875190404608N/A
9/30/20232,803168389596N/A
6/30/20232,731146373583N/A
3/31/20232,624167344557N/A
12/31/20222,517188314530N/A
9/30/20222,534267325557N/A
6/30/20222,550346335583N/A
3/31/20222,552384372611N/A
12/31/20212,553421409638N/A
9/30/20212,489444294517N/A
6/30/20212,425467179396N/A
3/31/20212,383449210430N/A
12/31/20202,341431240464N/A
9/30/20202,317472306521N/A
6/30/20202,292513372577N/A
3/31/20202,250500329525N/A
12/31/20192,207486286472N/A
9/30/20192,173424283452N/A
6/30/20192,138361279432N/A
3/31/20192,104322N/A431N/A
12/31/20182,070282N/A430N/A
9/30/20182,045-262N/A417N/A
6/30/20182,020-806N/A403N/A
3/31/20181,978-824N/A423N/A
12/31/20171,936-843N/A443N/A
9/30/20171,950-338N/A431N/A
6/30/20171,963166N/A419N/A
3/31/20171,957161N/A356N/A
12/31/20161,950155N/A293N/A
9/30/20161,782166N/A317N/A
6/30/20161,613176N/A340N/A
3/31/20161,527214N/A353N/A
12/31/20151,440252N/A366N/A
9/30/20151,450248N/A358N/A
6/30/20151,460243N/A350N/A
3/31/20151,475261N/A388N/A
12/31/20141,489278N/A425N/A
9/30/20141,477293N/A413N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HIK's forecast earnings growth (12.9% per year) is above the savings rate (2.7%).

Earnings vs Market: HIK's earnings (12.9% per year) are forecast to grow faster than the UK market (12.1% per year).

High Growth Earnings: HIK's earnings are forecast to grow, but not significantly.

Revenue vs Market: HIK's revenue (5.9% per year) is forecast to grow slower than the UK market (9.5% per year).

High Growth Revenue: HIK's revenue (5.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HIK's Return on Equity is forecast to be low in 3 years time (19.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/08/28 17:39
End of Day Share Price 2025/08/28 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Hikma Pharmaceuticals PLC is covered by 38 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kamla SinghAlphaValue
Emily FieldBarclays
Sidhartha ModiBarclays